{
  "docId": "019de070-d3cd-70da-8da9-11fac56c0e6a",
  "docSlug": "a10c554cbe4a4cf1ea91fc4610f64010",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 27 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 27,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-d3cd-70da-8da9-11fac56c0e6a/4",
  "deckHref": "/decks/019de070-d3cd-70da-8da9-11fac56c0e6a",
  "deckJsonHref": "/decks/019de070-d3cd-70da-8da9-11fac56c0e6a.json",
  "deckAnchorHref": "/decks/019de070-d3cd-70da-8da9-11fac56c0e6a#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.22,
        "x": 0.74,
        "y": 0.04
      },
      "kind": "image",
      "text": "NeuroBo Pharmaceuticals",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad234e9b-a60b-4c32-b82b-c03270e7de26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Pipeline Programs Addressing Large Unmet Needs\nGemcabene: Assessing for acute COVID-19\n- 25 Phase 1 and Phase 2 trials completed in Chronic Orphan Dyslipidemia indications\nNB-01–Targeting Pain in Orphan Indication\n- Compelling Phase 2 data showing evidence of efficacy and safety for neuropathic pain\n- Multimodal mechanism of action to treat pain supported by preclinical evidence\nNB-02–Targeting Alzheimer’s Disease (AD) and other dementias\n- IND Ready; compelling preclinical data",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e644eff-e90e-4088-85b4-8d48713251ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Repurposing ANA001 as a rapid COVID-19 treatment (Priority)\nANA001–COVID-19 Trial\n- Compelling in-vitro data showing evidence of efficacy, with 50+ years of safety data\n- Shows great broad-spectrum antiviral activity\n- Shows anti-inflammatory properties, without suppressing immune response\n- Shows promise as a prophylactic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faaff19d-0947-4a6f-a6c5-fb3e74822a37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Company Overview and Merger with ANA Therapeutics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7263e81b-20fd-48ce-8028-1422cf6d4f09",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "4a5aadff-d9f2-40d1-b410-4e943a661c0c",
      "evidence": "This slide is titled 'Company Overview and Merger with ANA Therapeutics' and provides a brief summary of the company's pipeline programs.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}